SCHEMBL4287562

SCHEMBL4287562

CCC(=O)c1ccc(Cl)nc1NC(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.40
ALDH1A1 P00352 4/20 0.40
MEN1 O00255 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
KDM4E B2RXH2 2/20 0.40
POLB P06746 1/20 0.38
MAPT P10636 5/20 0.38
GABRP O00591 1/20 0.37
GABRD O14764 1/20 0.37
GABRA1 P14867 1/20 0.37
GABRB1 P18505 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37
GABRA3 P34903 1/20 0.37
GABRA2 P47869 1/20 0.37
GABRB2 P47870 1/20 0.37
GABRA4 P48169 1/20 0.37
GABRE P78334 1/20 0.37
GABRA6 Q16445 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3596073 0.82 AHR (0.38) KMT2AALDH1A1MEN1SMN1; SMN2KDM4E
SCHEMBL7999892 0.81 ATR (0.42) KMT2AALDH1A1MEN1KDM4EPOLB
SCHEMBL8547431 0.76 HSP90AB1 (0.43) KMT2AALDH1A1MEN1SMN1; SMN2KDM4E
SCHEMBL1514134 0.75 XPO1 (0.41) KMT2AALDH1A1MEN1MAPTGAA
SCHEMBL27785442 0.75 HSP90AB1 (0.42) KMT2AALDH1A1MEN1SMN1; SMN2KDM4E
SCHEMBL28782731 0.74 KMT2A (0.41) KMT2AALDH1A1MEN1MAPTGAA
SCHEMBL19093153 0.74 KMT2A (0.41) KMT2AALDH1A1MEN1MAPTGAA
SCHEMBL16533890 0.73 HSP90AB1 (0.41) KMT2AALDH1A1MEN1SMN1; SMN2KDM4E
SCHEMBL2215231 0.73 HTT (0.53) KMT2AALDH1A1MEN1SMN1; SMN2KDM4E
SCHEMBL27739810 0.71 MAPT (0.39) KMT2AALDH1A1MEN1MAPTGABRP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130296343-A1 SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2013-11-07 US disclosed
US-20090258877-A1 TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE BAYER HEALTHCARE AG (DE) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258877-A1 TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE THPO, IL5, TPMT KMT2A 1387/4885ALDH1A1 3414/4885MEN1 2668/4885
US-20130296343-A1 SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES THPO, IKZF3, TPMT KMT2A 880/4885ALDH1A1 2442/4885MEN1 2496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.